Integra Lifesciences (NASDAQ:IART) issued its quarterly earnings data on Wednesday. The life sciences company reported $0.59 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.59, MarketWatch Earnings reports. The business had revenue of $365.85 million for the quarter, compared to the consensus estimate of $367.89 million. Integra Lifesciences had a return on equity of 17.43% and a net margin of 5.10%. The firm’s revenue was up 31.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.45 EPS. Integra Lifesciences updated its FY 2018 guidance to $2.36-2.42 EPS and its FY18 guidance to $2.36-2.42 EPS.
Shares of NASDAQ IART traded down $8.54 during mid-day trading on Wednesday, hitting $53.78. The company had a trading volume of 27,916 shares, compared to its average volume of 468,548. The stock has a market capitalization of $5.20 billion, a price-to-earnings ratio of 27.85, a PEG ratio of 1.89 and a beta of 0.57. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.52 and a quick ratio of 2.27. Integra Lifesciences has a one year low of $45.96 and a one year high of $67.50.
Several analysts recently commented on the company. Morgan Stanley set a $68.00 price objective on Integra Lifesciences and gave the stock a “hold” rating in a research note on Thursday, October 11th. BidaskClub cut Integra Lifesciences from a “buy” rating to a “hold” rating in a report on Friday, July 27th. Cantor Fitzgerald reiterated a “hold” rating and set a $59.00 target price on shares of Integra Lifesciences in a report on Wednesday, July 25th. Zacks Investment Research upgraded Integra Lifesciences from a “sell” rating to a “hold” rating in a report on Tuesday, October 9th. Finally, Oppenheimer reiterated a “buy” rating and set a $74.00 target price on shares of Integra Lifesciences in a report on Wednesday, July 25th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $62.15.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
See Also: Return on Equity (ROE)
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.